 ft 28 92 intern compani news mix result post japan drug sector product boost bottom line lead pharmaceut compani  japan top pharmaceut compani reveal mix result year march market product record strong perform turn lower profit sankyo largest industri post solid earn period sale mevalotin anti hyperlipedem drug yamanouchi pharmaceut anti ulcer treatment tanab seiyaku post 6 9 cent rise pre tax profit y13 1bn dollar 101 55m benefit strong sale product takeda chemic industri japan largest drug maker profit drop fujisawa pharmaceut post 16 3 cent fall pre tax profit sale anti ulcer drug fail reach expect level takeda tax profit fell 12 5 cent y32 5bn part reflect capit loss typhoon fujisawa record higher oper cost rise fund expens compani unveil lower pre tax profit includ eisai report 9 5 cent declin y31 2bn dainippon pharmaceut drop 10 5 cent y9 4bn current year march 1993 japanes pharmaceut compani face effect offici drug price cut approv ministri health welfar april impact compani heavi depend sale antibiot expect greater industri mr mitsuo ohmi pharmaceut analyst barclay de zoet wedd tokyo sector introduc high margin product offset price cut takeda forecast 0 2 cent increas pre tax profit y71 5bn 3 4 cent rise sale y580bn sankyo expect 12 cent rise pre tax profit y58bn 7 cent increas sale y385bn  top japanes pharmaceut compani  sale chang pre tax chang profit  takeda 560 9 1 8 71 3 3 1 sankyo 359 5 6 9 51 8 19 0 fujisawa 226 5 2 4 15 5 16 3 yamanouchi 225 9 6 0 61 1 2 5  ybn year end march  